The foundation stone of the GeneCity building, commissioned by Teknologiakiinteistöt, was laid on Thursday, November 2. GeneCity is a pharmaceutical factory being developed by Teknologiakiinteistöt for the biological drug contract manufacturer Biovian Oy.
The approximately 6,300-square-meter GeneCity will be located in Itäharju at Teollisuuskatu 42. The project includes a single-story production facility, lobby and office spaces spread over three floors, and social, storage, and utility spaces in the building's basement. The building will be completed at the end of 2024.
GeneCity's future tenant, Biovian, is one of the most significant players in the biotech sector in the Turku region, employing nearly 200 people. Currently, Biovian is a client of Teknologiakiinteistöt in BioCity, PharmaCity, and ElectroCity, where it occupies approximately 5,100 square meters of production and office space.
The speakers at the foundation stone laying ceremony held on Thursday, November 2, were Mayor of Turku Minna Arve, Construction Director at Teknologiakiinteistöt Miika Tuominen, CEO of Rakennustoimisto Lundén Janne Lundén, and CEO of Biovian Antti Nieminen.
GeneCity's future tenant, Biovian, is one of the most significant players in the biotech sector in the Turku region.
During the event, a metal cylinder was cast into the floor for future generations. Inside the cylinder are documents about the construction project, the day's Turun Sanomat newspaper reflecting the current era, coins, a list of event participants, a photograph of the Biovian staff, and laboratory supplies used at the pharmaceutical factory.
The architectural design for GeneCity was created by Sigge Arkkitehdit Oy. The building's cleanroom was designed by Elomatic Solutions Oy, which is also responsible for its implementation. The contractor for the project is Rakennustoimisto Lundén Oy. The building is being developed in accordance with the LEED v4 Platinum level, meaning the property's environmental impact and energy consumption are aimed to be minimized throughout its lifecycle.
GeneCity in brief:
- • Biovianille toteuttava lääketehdas
- • Valmistuu loppuvuonna 2024
- • Kokonaisala noin 6300 m²
- • Rakennuttaja Turun Teknologiakiinteistöt
- • Suunnittelija Sigge Arkkitehdit
- • Rakentaja Rakennustoimisto Lundén
- • Toteutetaan Leed-sertifikaatin v4-version Platina-tason mukaisesti
More information:
Miika Tuominen
Construction Director, Turun Teknologiakiinteistöt Oy
Tel. 050 339 3439
Antti Nieminen
CEO, Biovian Oy
Tel. 040 502 1332